Glycominds For Profit
IBDX® is the most validated and cost-effective serological panel to aid in the differential diagnosis of IBD vs. non-IBD and for CD vs. UC, as well as for predicting the probability of Crohn's Disease progression.
Headquarters:
Lod, HaMerkaz, Israel
Funding Status:
N/A
Employee Number:
11-50
Estimated Revenue:
$1.4Mper year
Investment Stage:
N/A
Number Of Exists:
N/A
Technology:
Biomarker panels
Investor Type:
N/A
Founded Date:
1999-01-01
Industry:
Clinical Data Management